PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-UK's Johnson warns lockdown, not vaccines, behind drop in COVID deaths

Tue, 13th Apr 2021 10:18

* Britain has offered shots to high-priority groups

* Johnson: lockdown largely behind lower cases

* PM cautions there will be more hospitalisations, deaths

* Moderna rollout begins in England

* Surge testing in London to track South Africa variant
(Recasts with Johnson, adds detail from health service)

By Alistair Smout and Sarah Young

LONDON, April 13 (Reuters) - British Prime Minister Boris
Johnson warned on Tuesday that the rapid drop in COVID-19 deaths
was largely down to a three-month lockdown, not the vaccination
programme, and that cases would rise once again as restrictions
ease.

The United Kingdom launched its inoculation drive in
December and has already offered a first shot to all over-50s,
the clinically vulnerable and health workers. The country is
behind only Israel in the proportion of its population to have
received at least one dose.

That rollout was however followed a month later by a third
lockdown in early January to tackle surging infections driven by
the "Kent" variant of the virus. Since February, daily infection
numbers, hospitalisations and deaths have all dropped sharply.

"The bulk of the work in reducing the disease has been done
by the lockdown," Johnson said on Tuesday, adding there was no
reason to change the roadmap for reopening the economy.

"As we unlock the result will inevitably be that we will see
more infections and sadly we will see more hospitalizations and
deaths."

With conditions improving, England reopened all retail,
hairdressers, gyms and pub gardens on Monday and Scotland,
Northern Ireland and Wales are due to reopen different elements
of their societies in the coming weeks.

The vaccine rollout also got a boost on Tuesday when Moderna
became the third vaccine to be offered in England after
AstraZeneca and one from Pfizer-BioNTech .

That will help keep Britain on track to hit its target of
offering all adults a vaccine by the end of July.

Moderna, already offered in the United States and Europe,
uses the same mRNA technology as Pfizer's shots but can be
stored at normal fridge temperatures unlike its rival U.S.
vaccine, which must be kept and shipped at ultra-low
temperatures.

On Tuesday, NHS England said that people aged 45 or over
could now book appointments to receive a COVID-19 vaccine.
For those categories already offered a vaccine, it said that 95%
of people who were eligible had taken up the offer.

However, in another note of caution to the optimism, the
government announced an expansion of so-called surge testing in
the south London boroughs of Lambeth and Wandsworth to detect
cases of the variant first found in South Africa.

There have been 74 confirmed and probable cases of the
coronavirus variant, known as B.1.351, in the boroughs, and
there is concern that vaccines are less effective against it.

"The important thing will be to watch: If the South African
variant has really taken off, and we'll probably know in about
two to three weeks, then we may need to pause re-opening a
little bit," James Naismith, professor of structural biology at
the University of Oxford and director of Rosalind Franklin
Institute, told BBC Radio.

With more than 127,000 fatalities, the United Kingdom has
the fifth-highest death toll in the world from COVID-19.
(additional reporting by Paul Sandle; Writing by Kate Holton;
Editing by Nick Macfie, Jon Boyle and Chizu Nomiyama)

More News
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.